StockData
Alzamend Neuro, Inc. logo

Alzamend Neuro, Inc. (ALZN) stock

ALZNNasdaqPharmaceutical PreparationsFiscal year ends April 30
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 10, 2026Score 4/30
$1.04−0.09 (-7.96%)

Close on Nov 18, 2026Market cap $5.02MP/E –Yield –

Earnings

Alzamend Neuro's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue, Q3 FY2023
–
EPS, Q3 FY2023
-$0.06
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Alzamend Neuro's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2025ended Apr 30, 2025Jul 23, 2025after the close–––Release
Q3 FY2023ended Jan 31, 2023Mar 16, 2023after the close––-$0.06Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Alzamend Neuro has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Alzamend Neuro puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Alzamend Neuro filed with the SEC as exhibits to Form 8-K or 6-K

  1. Update
  2. Results
  3. Update
  4. Results
  5. Update
  6. Update
  7. Update
  8. Update
  9. Update
  10. Update
  11. Update
  12. Update
  13. Update
  14. Update
  15. Update

See a number that looks wrong?